C=o Other Than As Ketone Or Aldehyde, Attached Directly Or Indirectly To Phosphorus Patents (Class 514/120)
  • Patent number: 10023912
    Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: July 17, 2018
    Assignee: EXIQON A/S
    Inventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
  • Patent number: 9963443
    Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: May 8, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Shuhei Ikeda
  • Patent number: 9925213
    Abstract: Non-natural oligomers have recently shown promise as functional analogs of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of ?-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: March 27, 2018
    Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, NORTHWESTERN UNIVERSITY
    Inventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
  • Patent number: 9775850
    Abstract: The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The methods of curing a patient of migraines having trigeminal or occipital neuralgia involves administering, by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: October 3, 2017
    Inventor: Faro Owiesy
  • Patent number: 9295683
    Abstract: The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 29, 2016
    Assignee: AKER BIOMARINE ANTARCTIC AS
    Inventors: Kjetil Berge, Lena Burri
  • Patent number: 9040505
    Abstract: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: May 26, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Mark R. Kelley
  • Publication number: 20150110866
    Abstract: A complex is provided, including a phospholipid and curcumin, wherein some or all of the phospholipid is a marine phospholipid. In addition, a composition is provided including a complex with a phospholipid and curcumin, wherein some or all of the phospholipid in the complex is a marine phospholipid. In addition, a method is provided of preparing a complex or composition including the steps of: a) forming a first solution by dissolving a quantity of curcumin in a solvent; b) forming a further solution by adding slowly to the first solution a suitable quantity of a marine phospholipid; c) processing the further solution to form the complex; and d) separating the complex from the solvent by distillation.
    Type: Application
    Filed: December 24, 2014
    Publication date: April 23, 2015
    Inventor: Harold Gordon Cave
  • Patent number: 9006219
    Abstract: The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: April 14, 2015
    Assignee: Nektar Therapeutics
    Inventors: Timothy A. Riley, Lin Cheng
  • Patent number: 9006144
    Abstract: Aqueous glyphosate formulations comprising a surfactant derived from metathesized natural oil feedstocks are disclosed. The formulations comprise a glyphosate salt, water, and a surfactant derived from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives. The surfactant is selected from C10 or C12 amine oxides, C10 or C12 quats, C10, C12, or C16 amidoamines, C10 or C12 amidoamine oxides, C10 imidazoline quats, C10 or C12 amidoamine quats, C10, C12, or C16 betaines, C16 amidoamine betaines, C18 diamidoamines, C18 diamidoamine oxides, C18 diamidoamine diquats, C18 diamidoamine oxide quats, C18 diamidoamine oxide betaines, Cis diamidoamine monobetaines, C18 diamidoamine monobetaine quats, C18 ester amidoamine quats, and amidoamines and their oxidized or quaternized derivatives made from self- or cross-metathesized palm or soybean oil.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: April 14, 2015
    Assignee: Stepan Company
    Inventors: Dave R. Allen, Randal J. Bernhardt, Andrew D. Malec, Patrick Shane Wolfe
  • Publication number: 20150087621
    Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Inventors: Federica Pericle, Jeremy A. Ross
  • Publication number: 20150087510
    Abstract: Fungicidal mixtures, comprising as active components 1) at least one 1-methylpyrazol-4-ylcarboxanilide of the formula I where R1?C1-C4-alkyl or C1-C4-haloalkyl, R2=hydrogen or halogen, X=hydrogen or halogen, Q=direct bond, a cyclopropylene or an anellated bicyclo[2.2.
    Type: Application
    Filed: September 29, 2014
    Publication date: March 26, 2015
    Inventors: Markus GEWEHR, Ulf GROEGER, Egon HADEN, Michael VONEND
  • Patent number: 8962600
    Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: February 24, 2015
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
  • Publication number: 20150030541
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventor: Thomas E. Rogers
  • Publication number: 20140378529
    Abstract: Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 25, 2014
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Florian L. Muller, Eliot Fletcher-Sananikone, Simona Colla, Elisa Aquilanti, Ronald DePinho
  • Publication number: 20140371177
    Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
  • Patent number: 8883765
    Abstract: Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotoxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: November 11, 2014
    Assignee: The John Hopkins University
    Inventors: Ravit Arav-Boger, Gary Posner
  • Publication number: 20140329775
    Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.
    Type: Application
    Filed: February 17, 2014
    Publication date: November 6, 2014
    Inventor: Scott G. Petersen
  • Publication number: 20140315834
    Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.
    Type: Application
    Filed: September 23, 2013
    Publication date: October 23, 2014
    Applicant: Medicon Pharmaceuticals, Inc.
    Inventor: Basil RIGAS
  • Patent number: 8865685
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: October 21, 2014
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventor: Annabelle Gallois-Bernos
  • Publication number: 20140301979
    Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Applicant: SIGA TECHNOLOGIES, INC.,
    Inventors: Sean M. AMBERG, Dongcheng DAI, Tove C. BOLKEN, Dennis E. HRUBY
  • Patent number: 8853195
    Abstract: Disclosed is a composition for reducing the exudation of the serum proteins. More specifically the composition of the present invention relates to a composition capable of improving conditions such as atopic dermatitis, atopic eczema, skin pruritus, atopic nasitis, atopic erythema or erythroderma, contact dermatitis, asthma, chronic obstructive pulmonary disease, etc. by reducing the exudation of the serum proteins in skin and mucosa.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: October 7, 2014
    Assignee: KT & G Corporation
    Inventor: Seong-hyun Choi
  • Patent number: 8846567
    Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from the class of the organophosphates or carbamates, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: September 30, 2014
    Assignee: Bayer CropScience AG
    Inventors: Heike Hungenberg, Peter Jeschke, Robert Velten, Wolfgang Thielert
  • Publication number: 20140288017
    Abstract: The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 25, 2014
    Inventors: William L. Jorgensen, Karen S. Anderson
  • Publication number: 20140274968
    Abstract: The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventors: Kjetil Berge, Lena Burri
  • Publication number: 20140274967
    Abstract: This invention relates generally to polyisoprenyl phosphonate derivatives pharmaceutical compositions comprising polyisoprenyl phosphonate derivatives, and uses thereof.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: William Boyle, Naoki Nakayama
  • Patent number: 8796243
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: August 5, 2014
    Assignee: National Jewish Health
    Inventor: Dennis R. Voelker
  • Patent number: 8778914
    Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 15, 2014
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Katrin Hochdoerffer
  • Patent number: 8759315
    Abstract: A ribose-related compound is added to whole blood or packed red cells which have suboptimal function as measured by decreased levels of 2,3-DPG in order to rejuvenate the red blood cells to normal function as seen by raised levels of 2,3-DPG. Two representative ribose-related compounds are D-ribose and inosine.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: June 24, 2014
    Assignee: Viacell, LLC
    Inventors: John A St. Cyr, Daniel G Ericson, Clarence A Johnson
  • Publication number: 20140170112
    Abstract: In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 19, 2014
    Applicant: VICUS THERAPEUTICS, LLC
    Inventors: John Maki, Newell Bascomb, Timothy J. Turner, Fredric Young
  • Publication number: 20140141972
    Abstract: This invention pertains to methods for protecting a propagule or a plant grown therefrom from invertebrate pests comprising contacting the propagule or the locus of the propagule with a biologically effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof wherein A and B and R1 through R8 are as defined in the disclosure. This invention also relates to propagules treated with a compound of Formula I and compositions comprising a Formula I compound for coating propagules.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: E I DU PONT NEMOURS AND COMPANY
    Inventors: RICHARD ALAN BERGER, Isaac Billy Annan, George Philip Lahm, John Lindsey Flexner, Thomas Paul Selby, Thomas Martin Stevenson
  • Publication number: 20140140973
    Abstract: This invention pertains to a method for controlling lepidopteran, homopteran, hemipteran, thysanopteran and coleopteran insect pests comprising contacting the insects or their environment with an arthropodicidally effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof wherein A and B and R1 through R8 are as defined in the disclosure. This invention further relates to a bezoxazinone compound of Formula 10 wherein R4 through R8 are as defined in the disclosure, useful for preparation of a compound of Formula I.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: GEORGE PHILIP LAHM, Stephen Frederick McCann, Kanu Maganbhai Patel, Thomas Paul Selby, Thomas Martin Stevenson
  • Patent number: 8722649
    Abstract: Described herein is the synthesis and pharmacology of a series of ?-substituted methylene phosphonate analogs, in which the ?-CH2 moiety is replaced with CHCl or CHBr.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: May 13, 2014
    Assignees: University of Utah Research Foundation, University of Tennessee Research Foundation
    Inventors: Glenn Prestwich, Gabor Tigyi, Guowei Jiang, Guanghui Yang, Joanna Gajewiak, Honglu Zhang, Xiaoyu Xu
  • Patent number: 8709454
    Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 29, 2014
    Assignee: L'Oreal
    Inventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
  • Patent number: 8710033
    Abstract: The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic acids selected from the group consisting of LPA-C16:0, LPA-C16:1, LPA-C18:0, LPA-C18:1 and LPA-C18:2.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: April 29, 2014
    Assignees: JCR Pharmaceuticals Co., Ltd.
    Inventors: Masahide Shiotani, Sakae Goto, Mitsuo Shimizu
  • Publication number: 20140088045
    Abstract: The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and/or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and/or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 27, 2014
    Inventors: Basil Rigas, Jason B. Rigas
  • Publication number: 20140088044
    Abstract: The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 27, 2014
    Inventors: Basil Rigas, Jason B. Rigas
  • Publication number: 20140088047
    Abstract: The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 27, 2014
    Applicant: AKER BIOASSIST AS
    Inventors: Nils Hoem, Elizabeth B. Vadas
  • Patent number: 8680080
    Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 25, 2014
    Assignee: Neptune Technologies & Bioressources, Inc.
    Inventor: Fotini Sampalis
  • Publication number: 20140080791
    Abstract: The invention relates to omega-3 phospholipid supplements for females, and in particular to omega-3 phospholipid supplements with increased bioavailability as evidenced by increased EPA and DHA in plasma phospholipids and an increase in omega-3 index as compared to males. In preferred embodiments, the omega-3 phospholipid is krill oil.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 20, 2014
    Inventors: Kjetil Berge, Nils Hoem
  • Publication number: 20140044690
    Abstract: A method of treating or preventing a neurodegenerative disease includes administering an effective amount of a compound to a subject in need thereof. The compound includes a high-energy compound, such as adenosine triphosphate (ATP), guanosine triphosphate (GTP), phosphocreatine (PCr), acetyl coenzyme A (ACoA), phosphoenol pyruvate (PEP), or a combination thereof.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 13, 2014
    Applicants: U.S. Department of Veterans Affairs
    Inventors: Ming CHEN, Darrell R. Sawmiller, Huey T. Nguyen
  • Publication number: 20130338113
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Application
    Filed: April 4, 2013
    Publication date: December 19, 2013
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: HAO YI LIANG, FRANCIS CHI, QINGFU XU, BILL PIU CHAN
  • Patent number: 8586567
    Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 19, 2013
    Assignee: Acasti Pharma, Inc.
    Inventors: Fotini Sampalis, Henri Harland
  • Publication number: 20130296271
    Abstract: Agri-horticultural pest control compositions having outstanding control effect on pests, in particular, agri-horticultural pests, which comprise as active ingredients one or more 4-(3-butynyl)aminopyrimidine derivatives represented by the general formula [I], namely, where R1 is typically selected from among: a) phenyl c) —SiR5R6R7 (R5, R6, and R7 which may be the same or different represent a linear or branched alkyl having 1-6 carbon atoms, a linear or branched haloalkyl having 1-3 carbon atoms which is substituted by one halogen atom, a linear or branched cyanoalkyl having 1-3 carbon atoms which is substituted by one cyano group, and phenyl); d) hydropgen atom; R2 typically represents a hydrogen atom; R3 typically represents a hydrogen atom; R4 represents a hydrogen atom and one or more agri-horticultural pest control compounds selected from among agri-horticultural antimicrobial compounds, say, multi-site contact active compouns, nucleic acids synthesis inhibitory active compounds, mitosis and cell
    Type: Application
    Filed: December 27, 2011
    Publication date: November 7, 2013
    Applicant: SDS Biotech K.K.
    Inventors: Masaaki Sakai, Tomoaki Matsumura, Satohiro Midorikawa, Takashi Nomoto, Tomoko Muraki, Ryutaro Katsuki
  • Patent number: 8568773
    Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: October 29, 2013
    Assignee: Enzymotec Ltd.
    Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled, Yael Richter
  • Publication number: 20130281410
    Abstract: The invention provides methods for the treatment of major depressive disorder in male subjects and methods for the treatment of psychiatric disorders at high altitudes by administering one or more creatine-containing compounds.
    Type: Application
    Filed: May 13, 2011
    Publication date: October 24, 2013
    Applicants: University of Utah Research Foundation, The McLean Hospital Corporation
    Inventor: Perry F. Renshaw
  • Publication number: 20130244984
    Abstract: Provided are a drug, a cosmetic, etc. for promoting production of ceramide. Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8 to 24 carbon atoms, and R3 represents an alkyl group having 1 to 24 carbon atoms when R1 represents a phosphono group or represents a phosphono group when R1 represents a hydrogen atom, or a salt thereof as an active ingredient.
    Type: Application
    Filed: April 25, 2013
    Publication date: September 19, 2013
    Applicant: Kao Corporation
    Inventors: Yoshiya SUGAI, Hiroshi HASHIMOTO, Shinya AMANO, Shotaro ITO, Yoshie SHIMOTOYODOME, Yoriko NAKAGIRI
  • Patent number: 8530484
    Abstract: The method includes the steps of cleansing of the scalp sufficiently to remove material which would otherwise block antiviral medication from reaching hair follicles, heating the scalp to increase the absorption of the antiviral medication and applying the antiviral medication to the scalp in effective amount to suppress viral replication or viral activation present in the nerves leading to the scalp.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: September 10, 2013
    Assignee: Loreal SA
    Inventor: Robert E Akridge
  • Patent number: 8524690
    Abstract: A topical composition containing a DNA polymerase inhibitor for removing hair as well as methods of inducing hair loss is described.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: September 3, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Carmela Vittorio
  • Publication number: 20130225529
    Abstract: Phospho-ester compounds and pharmaceutical compositions thereof administered by the respiratory and other routes for the prevention and/or treatment of lung and brain cancer and precancerous conditions thereof, for the treatment of pain, for the treatment of skin disorders, for treating and/or preventing inflammation-related diseases, and for the treatment and prevention of cancer.
    Type: Application
    Filed: February 27, 2013
    Publication date: August 29, 2013
    Inventor: Basil RIGAS
  • Publication number: 20130225533
    Abstract: Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, wherein about 25% of the total 4,7,10,13,16,19-docosahexaenoic acid moieties in the composition are covalently bound to phospholipids, and wherein components (1) and (2) are present in amounts effective to support overall neurological health in a subject.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 29, 2013
    Applicant: Nordic Naturals, Inc.
    Inventor: Nordic Naturals, Inc.